Evidence map›Paper›PMID 36009058›Full record

ReviewBrain sciences2022

Coexistence of Myelin Oligodendrocyte Glycoprotein Immunoglobulin G and Neuronal or Glial Antibodies in the Central Nervous System: A Systematic Review.

Cong Zhao, Pei Liu, Daidi Zhao, Jiaqi Ding, Guangyun Zhang, Hongzeng Li, Jun Guo

Open access · goldAbstract readReview
In one paragraph

Review in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Cong ZhaoDepartment of Neurology, Air Force Medical Center of PLA, Beijing 100142, China.
Pei LiuDepartment of Neurology, Xi'an City First Hospital, Xi'an 710002, China.
Daidi ZhaoDepartment of Neurology, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China.
Jiaqi DingDepartment of Neurology, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China.
Guangyun ZhangDepartment of Neurology, Air Force Medical Center of PLA, Beijing 100142, China.
Hongzeng LiDepartment of Neurology, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China.
Jun GuoDepartment of Neurology, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China.ORCID 0000-0001-8053-881X
Air Force Medical University · CNAir Force General Hospital PLA · CNFirst Hospital of Xi'an · CN

Funding

Key Research and Development Project of Shaanxi Province 2022ZDLSF02-04National Natural Science Foundation of China 81901226National Natural Science Foundation of China 82171399
6 · The paper itself

Abstract

backgroundMyelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) has been considered a diagnostic marker for patients with demyelinating disease, termed "MOG-IgG associated disorder" (MOGAD). Recently, the coexistence of MOG-IgG and other neuronal or glial antibodies has attracted extensive attention from clinicians. In this article, we systematically review the characteristics of MOG-IgG-related antibody coexistence syndrome.

methodsTwo authors independently searched PubMed for relevant studies published before October 2021. We also manually searched the references of each related article. The appropriateness of the included studies was assessed by reading the titles, abstracts, and full texts if necessary.

resultsThirty-five relevant publications that met our inclusion criteria were finally included, of which fourteen were retrospective studies and twenty-one were case reports. A total of 113 patients were reported to show the coexistence of MOG-IgG and neuronal or glial antibodies. Additionally, 68.14% of patients were double positive for MOG-IgG and N-Methyl-D-Aspartate Receptor-IgG (NMDAR-IgG), followed by 23.01% of patients who were double positive for MOG-IgG and aquaporin4-IgG (AQP4-IgG). Encephalitis was the predominant phenotype when MOG-IgG coexisted with NMDAR-IgG, probably accompanied by imaging features of demyelination. Patients with dual positivity for MOG-IgG and AQP4-IgG experienced more severe disease and more frequent relapses. The coexistence of MOG-IgG and antibodies other than NMDAR-IgG and AQP4-IgG was extremely rare, and the clinical presentations were diverse and atypical. Except for patients who were double positive for MOG-IgG and AQP4-IgG, most patients with multiple antibodies had a good prognosis.

conclusionsMOG-IgG may coexist with neuronal or glial antibodies. Expanded screening for neuronal or glial antibodies should be performed in patients with atypical clinical and radiological features.

Indexed as

antibodiescoexistencemyelin oligodendrocyte glycoproteinN-Methyl-D-Aspartate Receptorsystematic review

Identifiers

PMID36009058
PMCPMC9405704
OpenAlexW4288060599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.